CAMBRIDGE, England, April 26, 2017 /PRNewswire/ -- Proximagen Limited (Proximagen) today announced that its pivotal Phase 3 trial of intranasal midazolam (USL261) for the rescue treatment of seizure ...
About NAYZILAM1NAYZILAM® (midazolam) nasal spray CIV is a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, ...
Patients treated with 5-mg midazolam nasal spray were more likely than those given placebo to remain seizure free for 6 hours after treatment or have their seizure terminated within 10 minutes, with ...
The NDA includes data from the Phase 3 ARTEMIS 1 trial which evaluated the intranasal spray in 292 patients. The Food and Drug Administration (FDA) has accepted for review the New Drug Application ...
The use of nasal sprays for the treatment of epilepsy has gained considerable attention lately. At this past May's American Academy of Neurology (AAN) meeting, Washington University epileptologist R.
The Food and Drug Administration (FDA) has approved Nayzilam (midazolam) nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity The Food and Drug ...
The FDA approves UCB SA's (OTCPK:UCBJY) NAYZILAM (midazolam) nasal spray CIV for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute ...
The Multidisciplinary Committee of Experts (MDC), which advices the National Pharmaceutical Pricing Authority (NPPA) on price related matters, recommended obtaining views from the Standing National ...
* MIDAZOLAM NASAL SPRAY HAS ALSO BEEN GRANTED FAST TRACK DESIGNATION BY THE US FDA DUE TO THE HIGH UNMET NEED FOR PATIENTS AND CAREGIVERS * MIDAZOLAM NASAL SPRAY HAS BEEN GRANTED ORPHAN DRUG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback